In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Introducing: Machines Like Us
Alice Munro, remembered
How Ottawa is preparing for a possible second Trump term
Hydrogen trains might be the future of Canadian rail
How nurse practitioners could help Canada’s primary care crisis
The problem with Canada’s affordable housing
The $34-billion bet on boosting Canada’s economy
Understanding Israel’s push into Rafah during ceasefire talks
TD Bank caught up in drug money-laundering scheme
How do we solve our global plastic problem?
Police, campus unrest and the power of student protests
The ‘stain’ of foreign interference on Canadian elections
‘What I eat in a day’ videos and the new diet culture
How the politics of decriminalization played out in B.C.
Why running is more popular than ever
Sudan and the neglected wars
The biggest EV investment in Canada yet
City Space: Vancouver’s Chinatown fights gentrification
The call to disband the Thunder Bay police
How Hong Kong is cracking down on dissent
Create your
podcast in
minutes
It is Free
As It Happens
The Daily
Morning Wire
Up First
Dobré ráno | Denný podcast denníka SME